In March 2024, AbbVie announced its decision to terminate the development of IMGC936 in collaboration with MacroGenics, citing that the clinical phase I trial results did not meet the expected safety and efficacy targets. IMGC936 was an antibody-drug conjugate (ADC) targeting ADAM9, initially developed through a partnership between ImmunoGen and MacroGenics, with each holding a […]
Membrane proteins are essential for cell functions such as maintaining cellular physiological processes, playing crucial roles in substance transport, signal transduction, and cell recognition. They constitute approximately 25% of the total proteome encoded by the human genome. Currently, membrane protein targets account for over 60% of known drug targets and over 90% of antibody drug […]
Seizure related 6 homolog (SZE6) is a transmembrane protein discovered on the surface of selected neuronal lineage cells. Its expression is limited in normal tissues but highly expressed in small cell lung cancer (SCLC), making it an ideal target for ADC (Antibody-Drug Conjugate) therapy. AbbVie presented early data on their SEZ6 ADC drug, ABBV-706, in […]
In March 2024, a preclinical study titled “Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models” was published in Molecular Cancer Therapeutics. This study demonstrated that Raludotatug Deruxtecan, developed by Daiichi Sankyo, is effective against human ovarian and kidney cancer models. Additionally, […]
At the 2024 ASCO Annual Meeting, one of the highlights was the MRG004A-001 study conducted by Professor Yu Xianjun’s team, marking a milestone in the exploration of escalating doses of MRG004A, an ADC drug targeting tissue factor TF/CD142. Carried out in the United States and China, the study’s findings are significant. Among 12 evaluated pancreatic […]
At the 2024 ASCO Annual Meeting, HANGZHOU DAC BIOTECHNOLOGY (abbreviated as DAC Biotech) presented preclinical data on their STEAP1 ADC, DXC008. This ADC targets both STEAP1 and PSMA, showing high affinity for STEAP1 and moderate affinity for PSMA. Preclinical data demonstrated that a single dose of 1 mpk produced durable anti-tumor responses in xenograft models […]
During the 2024 ASCO conference, Professor Zhang Jian of Fudan University’s Cancer Hospital unveiled the Phase I/II clinical trial outcomes for 9MW2821, an ADC drug targeting Nectin-4, designed to combat advanced solid tumors. The drug demonstrated promising results, particularly in treating urothelial carcinoma, cervical cancer, esophageal cancer, and triple-negative breast cancer. Concurrently, CSPS showcased their […]
The 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024) will take place in Chicago, USA, from May 31st to June 4th. As a major event in the cancer treatment community, it will reveal many important clinical research outcomes and the latest innovations. Antibody-drug conjugates (ADCs), which cleverly combine targeted antibody therapies with powerful […]
Folate receptor alpha (FRα), due to its differential expression in various tumor or cancer tissues compared to normal tissues, is considered an ideal druggable target. In the past, pharmaceutical companies have ventured into developing FRα-targeted therapies, including small molecule conjugates and monoclonal antibody drugs like Morphotek’s humanized monoclonal antibody farletuzumab, and Endocyte’s small molecule conjugate […]
In December 2023, GlaxoSmithKline (“GSK”) invested $1.71 billion to obtain the global exclusive rights for the development, production, and commercialization of HS-20093 from HANSON PHARAM (excluding mainland China, Hong Kong, Macau, and Taiwan). HS-20093 is a novel B7-H3 targeted antibody-drug conjugate (ADC) developed independently by HANSON PHARAM. Similarly, in April 2024, Macrogenics’ stock price surged […]